Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 1998 Dec 7;58(1):83–96. doi: 10.1016/S0168-1702(98)00104-X

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 1998 Elsevier Science B.V. All rights reserved.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Fig. 4 — Representative SDS-PAGE gels (left lane) and corresponding immunoblots of guinea pig anti-BRV-1 N protein preimmune (gpPI) and hyperimmune (gpHI) sera with (A) purified bovine torovirus-negative (BTV−) and positive (BTV+) fecal specimens, and (B) a purified human torovirus-positive fecal specimen. (C) SDS-PAGE gel of the expressed BRV-1 N protein from the insoluble E. coli fraction (left) and corresponding immunoblots of gpPI and gpHI sera, human acute (huA) and convalescent (huC) paired sera, and bovine anti-BRV-1 preimmune (bPI) and hyperimmune (bHI) sera.

Fig. 4 — Representative SDS-PAGE gels (left lane) and corresponding immunoblots of guinea pig anti-BRV-1 N protein preimmune (gpPI) and hyperimmune (gpHI) sera with (A) purified bovine torovirus-negative (BTV−) and positive (BTV+) fecal specimens, and (B) a purified human torovirus-positive fecal specimen. (C) SDS-PAGE gel of the expressed BRV-1 N protein from the insoluble E. coli fraction (left) and corresponding immunoblots of gpPI and gpHI sera, human acute (huA) and convalescent (huC) paired sera, and bovine anti-BRV-1 preimmune (bPI) and hyperimmune (bHI) sera.